Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Summit Insights Group Upgrades Lam Research to Buy

Summit Insights Group Upgrades Lam Research to Buy

Summit Insights Group analyst Kinngai Chan upgrades Lam Research (NASDAQ:LRCX) from Hold to Buy.

byBenzinga Newsdesk

October 20, 2022

1 minute read

Summit Insights Group analyst Kinngai Chan upgrades Lam Research (NASDAQ:LRCX) from Hold to Buy.

Why Is Gastrointestinal Disease Focused-RedHill Biopharma Stock Higher Over 100% Today?

By Vandana Singh

November 27, 10:15 AM

The FDA has granted five years' market exclusivity for RedHill Biopharma Ltd's (NASDAQ: RDHL) Talicia under the Generating Antibiotic Incentives Now Act Qualified Infectious Disease Product designation, as recommended by the

RDHL

Global
News

White House Spokesman Kirby Says Defense Dept Making Preliminary Explorations Into Feasability Of Potentially Providing Fighter Jets For Ukraine

By Benzinga Newsdesk

July 22, 2:04 PM

- Reuters

RSX

P/E Ratio Insights for Booking Holdings

By Benzinga Insights

March 31, 4:45 PM

In the current session, the stock is trading at $2652.41, after a 1.63% increase. Over the past month,…

BKNG

Analyst Ratings

Piper Sandler Maintains Overweight Rating for VectivBio Holding: Here’s What You Need To Know

By Benzinga Insights

April 20, 1:00 PM

Piper Sandler has decided to maintain its Overweight rating of VectivBio Holding (NASDAQ:VECT) and raise its price target…

VECT

Summit Insights Group Upgrades Lam Research to Buy

Related Posts

Why Is Gastrointestinal Disease Focused-RedHill Biopharma Stock Higher Over 100% Today?

White House Spokesman Kirby Says Defense Dept Making Preliminary Explorations Into Feasability Of Potentially Providing Fighter Jets For Ukraine

P/E Ratio Insights for Booking Holdings

Piper Sandler Maintains Overweight Rating for VectivBio Holding: Here’s What You Need To Know